Psychology Wiki


34,203pages on
this wiki
Add New Page
Talk0 Share

Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)

Tetrabenazine chemical structure

1,3,4,6,7,11b-Hexahydro- 9,10-dimethoxy-3- (2-methylpropyl)- 2H-benzo[a]quinoline; Ro-1-9569
IUPAC name
CAS number
ATC code


Chemical formula {{{chemical_formula}}}
Molecular weight 317.427
Elimination half-life
Pregnancy category
Legal status Orphan drug
Routes of administration tablets: 25 mg

Tetrabenazine is a drug for the symptomatical treatment of hyperkinetic movement disorder and is marketed under the trade names Nitoman® in Canada and Xenazine® in New Zealand and some parts of Europe, and is also available in the USA as an orphan drug. The compound is known since the 1950s. Tetrabenazine works mainly as a VMAT-inhibitor[1] and as such promotes the early metabolic degradation of the neurotransmitter dopamine.

Common usesEdit

Tetrabenazine is used as a treatment, but not a cure for hyperkinetic disorders[2] such as:

Side effectsEdit

Because tetrabenazine is closely related to the antipsychotics, many of its side effects are similar. Some of these include:

  • Depression - the most common side effect, reported in roughly 15% of those who take the medication
  • Dizziness/drowsiness
  • Akathisia (aka "restless pacing" - an inability to keep still, with intense anxiety when forced to do so)
  • Parkinsonism

Unlike many of the antipychotics, tetrabenazine is not known to cause Tardive dyskinesia, and in fact can be an effective treatment for the antipsychotic-induced movement disorder.


  • Because of the relatively high incidence of depression, it has been recommended that people with a history of depression avoid taking tetrabenazine. Research into this is ongoing however, and this warning may be dropped in the future.
  • The concomitant intake of MAO inhibitors is contraindicated.


  1. Guangrong Zheng et al. (2006): "Vesicular Monoamine Transporter 2: Role as a Novel Target for Drug Development", AAPSJ. Fulltext
  2. Jankovic J, Beach J (1997). Long-term effects of tetrabenazine in hyperkinetic movement disorders.. Neurology 48 (2): 358-62. PMID 9040721.

External linksEdit

Template:Other nervous system drugs]]

This page uses Creative Commons Licensed content from Wikipedia (view authors).

Ad blocker interference detected!

Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.

Also on Fandom

Random Wiki